Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
Recruiting
- Conditions
- Human Papillomavirus
- Interventions
- Diagnostic Test: Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 600
- Registration Number
- NCT06434337
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Phase 1
Recruiting
- Conditions
- Systemic SclerosisAutoimmune Disorders
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT06434363
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
Phase 1
Suspended
- Conditions
- Advanced Bladder Cancer
- Interventions
- Drug: Enfortumab VedotinRadiation: Radiation Therapy
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT06434350
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Virtual, Group-Based, Expressive Writing Intervention for Survivors of Adolescent and Young Adult Cancer
Not Applicable
Recruiting
- Conditions
- Cancer
- Interventions
- Behavioral: Behavioral Intervention
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06434402
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health
Recruiting
- Conditions
- Transplant and Cell Therapy
- Interventions
- Behavioral: Social Determinants of Health Questionnaire
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2000
- Registration Number
- NCT06431347
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Goals of Care Discussion for Patients with Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center
Not Applicable
Recruiting
- Conditions
- Lung CancerGastrointestinal Cancer
- Interventions
- Other: Standard of Care (Goals of Care)Other: Standard of Care (Acute Cancer Care Center)
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT06420206
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Early Phase 1
Recruiting
- Conditions
- Esophageal Cancer
- Interventions
- Drug: ArabinoFuranosylGuanine [18F]F-AraG
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06414902
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
Early Phase 1
Recruiting
- Conditions
- RUNX1 Familial Platelet Disorder
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT06414889
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Phase 1
Recruiting
- Conditions
- Metastatic Colorectal CancerKRAS G12C Mutations
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT06412198
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
Phase 2
Recruiting
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negativeMetastatic Invasive LObular Carcinoma
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT06408168
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath